Drew Thompson

Drew Thompson

Company: Fulcrum Therapeutics

Job title: Vice President - Molecular Innovation & Pharmaceutical Development


Next Generation Drug Discovery at Fulcrum Therapeutics: FTX-6058, A Novel EED Inhibitor To Increase Fetal Hemoglobin Expression For the Treatment of Select Hemoglobinopathies 2:30 pm

• Fulcrum Therapeutics identifies drug candidates to treat rare genetic diseases at their root cause • FulcrumSeek as a next generation Product Engine for drug discovery • Case Study 1: Discovery of FTX-6058, a novel EED inhibitor to increase fetal hemoglobin for the treatment of select hemoglobinopathiesRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.